|
HS Code |
967568 |
| Generic Name | Naloxone Hydrochloride |
| Brand Names | Narcan, Evzio |
| Drug Class | Opioid antagonist |
| Route Of Administration | Intravenous, intramuscular, subcutaneous, intranasal |
| Indication | Opioid overdose reversal |
| Molecular Formula | C19H21NO4·HCl |
| Mechanism Of Action | Competitive opioid receptor antagonist |
| Onset Of Action | 2 to 5 minutes (IM/IV) |
| Duration Of Action | 30 to 90 minutes |
| Pregnancy Category | Category B |
| Storage Conditions | Store at 20°C to 25°C (68°F to 77°F) |
| Appearance | Clear, colorless solution |
| Prescription Status | Prescription and over-the-counter (varies by country) |
| Metabolism | Hepatic |
| Excretion | Renal |
As an accredited Naloxone Hydrochloride factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | The packaging for Naloxone Hydrochloride typically consists of a 2 mg/2 mL pre-filled syringe in a labeled, tamper-evident carton. |
| Shipping | Naloxone Hydrochloride should be shipped in tightly sealed, clearly labeled containers, protected from light and moisture. Maintain appropriate temperature conditions, typically room temperature unless otherwise specified. Follow all applicable regulations for shipping pharmaceuticals, ensuring secure packaging to prevent damage or contamination throughout transit. Include relevant safety data and emergency contact information. |
| Storage | Naloxone Hydrochloride should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F), and protected from light. It should be kept in the original packaging until ready for use to prevent exposure to excessive moisture or temperature variations. The medication must be kept out of reach of children and disposed of properly after expiration. |
|
Purity 98%: Naloxone Hydrochloride with purity 98% is used in emergency opioid overdose reversal, where rapid restoration of normal respiration is achieved. Molecular Weight 363.84 g/mol: Naloxone Hydrochloride with molecular weight 363.84 g/mol is used in pharmaceutical injection formulations, where precise dosing accuracy is ensured. Melting Point 200-204°C: Naloxone Hydrochloride with a melting point of 200-204°C is used in clinical compounding settings, where stable handling under standard processing temperatures is required. Aqueous Solubility 10 mg/mL: Naloxone Hydrochloride with aqueous solubility of 10 mg/mL is used in intravenous delivery systems, where efficient absorption and rapid onset of action are attained. Stability Temperature 25°C: Naloxone Hydrochloride with stability at 25°C is used in standard pharmacy storage, where product degradation is minimized and shelf life is extended. Particle Size ≤ 10 µm: Naloxone Hydrochloride with particle size ≤ 10 µm is used in intranasal spray development, where uniform dispersion and high bioavailability are accomplished. |
Competitive Naloxone Hydrochloride prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Across the country, opioid overdoses disrupt lives and put families through unimaginable pain. Over the years, many families have lost loved ones simply because the right tools were out of reach. Naloxone Hydrochloride—often just called naloxone—stands out as an immediate answer. With years of study and experience behind it, this medication has changed how we approach overdose emergencies. As someone who has witnessed communities reeling from opioid misuse, I see a real difference when naloxone becomes accessible. It isn’t some mysterious drug; it’s a straightforward, science-based response to a very human problem.
Naloxone Hydrochloride goes straight to the core of opioid overdoses. It works as an opioid antagonist, meaning it pushes opioids off their receptors in the brain. Opioids slow breathing. In many cases, people stop breathing altogether. Time matters most during these emergencies. Naloxone doesn’t require a medical degree to use. Most formulations come in user-friendly models—a single-use prefilled syringe offered by one main brand, or an intranasal spray that requires just a squirt in the nostril. Some brands market ampoules or vials for those trained in injection, but the nasal spray changed the landscape, letting more people step in to help.
For community groups, law enforcement, and families, these details matter. The intranasal spray cuts down on training barriers and reduces hesitation. During training sessions in urban and rural settings alike, I’ve seen people go from hesitant to confident within minutes. They realize they don’t have to handle needles, measure doses, or prep complex equipment. Instead, with the spray, it’s a simple squeeze. This accessibility saves minutes, and minutes save lives.
Drug companies manufacture naloxone in a few key formats. The version that’s made the biggest difference in public health comes as a 4mg/0.1mL nasal spray. A second form, a 0.4mg/mL injectable solution, often arrives prefilled in a syringe or in small vials. Emergency medical professionals lean toward the injectable model because it hits the bloodstream quickly, which is crucial in severe cases. Lay responders—friends, family, bystanders—often lean toward the spray. Emergency departments, mobile response units, and even schools now keep both kinds, tailoring readiness to different comfort levels and skill sets.
Shelf-life makes a practical difference, too. Most nasal sprays don’t require refrigeration, which means storage isn’t limited to a hospital or ambulance bay. I’ve kept kits in my car, at the office, and even given them out at community events. That flexibility keeps naloxone close at hand. For populations at higher risk—people using prescription opioids, communities with high heroin or fentanyl use—easy access turns a bystander into a rescuer.
Here’s what sets naloxone apart: the speed and reliability with which it reverses opioid overdoses. This isn’t a theoretical benefit. Medical journals, government agencies, and my own experiences volunteering in harm reduction back this up. Most people who receive naloxone during an overdose regain consciousness within minutes. They begin to breathe again. In some cases, a second dose is needed, especially with strong synthetic opioids like fentanyl, but the concept stays the same. Naloxone doesn’t “treat addiction” or keep withdrawal away. It lets someone survive long enough to consider change—or just live another day.
Other overdose reversal products exist. Some operate as combination devices, mixing naloxone with other medications or additives. None have matched naloxone for reliability, straightforward use, or track record. The Food and Drug Administration recognized this, approving it for non-prescription sale in the United States. That decision signaled that the benefits far outweigh minimal risks.
I’ve watched cities roll out naloxone programs, handing out kits to police, library staff, and community organizations. At the street level, that looks like people walking with a clear plastic pouch clipped to their bag, a touch of hope in neighborhoods hit hardest by overdoses. Hospitals see fewer deaths, EMS teams get to more patients in time, and families have more chances to reunite. Statistical evidence backs this up: states that support naloxone distribution see drops in opioid-related deaths.
Stigma remains one hurdle. Some worry that making naloxone widely available might “encourage” riskier drug use. But public health research shows the opposite. People don’t seek out overdose experiences; they often fear them deeply. Naloxone gives a way to stay alive. This survival opens doors: every saved life can lead to recovery resources, social work interventions, and another shot at stability.
Administering naloxone starts with recognizing the signs of an opioid overdose: slow or stopped breathing, pinpoint pupils, unresponsive to voice or touch. In these moments, simplicity drives response. The intranasal device has printed instructions. You pull it from the packaging, insert the nozzle into one nostril, press the plunger, and wait. If the person doesn’t respond in two to three minutes, another dose can be given. For injectables, people with basic training use the prefilled syringe, injecting into a muscle. Training sessions walk through these steps until the physical act becomes muscle memory.
Everybody freezes up the first time. It is daunting to face a life-or-death crisis. But over the years, I’ve seen teenagers, teachers, bus drivers, and grandmothers pull through. Not because they’re fearless, but because the process is as direct as possible.
Naloxone doesn’t demand much for storage—a room-temperature shelf, away from direct sunlight, will do. Some kits include a card listing expiration dates. Many community providers run drives to replace expiring supplies. While manufacturers indicate that degraded medication may lose strength past expiry dates, studies suggest naloxone often retains potency even after expiration, making it a safer fallback than nothing at all.
From a legal standpoint, most US states now offer protection for people who administer naloxone in good faith—a “Good Samaritan” approach that shields those involved in rescue from prosecution for drug use or related issues at the scene. This peace of mind makes a difference for nervous responders.
The United States faces an opioid epidemic that cuts across rural, suburban, and urban lines. Overdose deaths have spiked as fentanyl and synthetic opioids spread, raising the stakes at every level. Naloxone isn’t a cure; it’s a crucial stopgap. Public health agencies, advocacy groups, and medical associations champion this tool because it works, and because the alternative is unacceptable. Many frontline responders argue that every public space—schools, hotels, transit stations—should stock naloxone the way they stock automated external defibrillators.
State and local governments have a place in this fight. Legislation helped make naloxone available over the counter, but implementation takes more than laws. It takes education, funding for bulk purchases, and outreach to teach people how and when to use naloxone. Many of the programs that really move the needle involve partnerships between people in recovery, affected families, doctors, and policymakers—a reminder that no one group owns this solution.
Even with growing awareness, access gaps still exist. In small towns and remote areas, pharmacies may not stock enough nasal spray or may sell it at a price families struggle to cover. Insurance coverage is inconsistent. Nonprofits and local governments can help close this gap by bulk-buying supplies, distributing free kits, and offering no-questions-asked training. In some cities, mobile vans roam neighborhoods to pass out naloxone and answer questions—a grassroots effort with proven results.
Worries over cost shouldn’t stop anyone from saving a life. Many national and state initiatives have poured funding specifically into community naloxone projects. For people who worry about using the drug “wrong,” repeated public information campaigns and hands-on practice workshops break down those fears. Nobody bats a thousand on their first try, but any effort is better than doing nothing.
Language and trust also play crucial roles. Some communities have deep skepticism about outsiders bearing medical solutions. Trusted peers, advocates with lived experience, and culturally specific outreach all bridge that gap. Translation of training materials, visual step-by-step cards, and even roleplay scenarios make a difference in confidence and follow-through.
A handful of other rescue options exist, including combination opioid antagonists or drugs with overlapping effects. These haven’t matched naloxone for several reasons. For one thing, naloxone works without producing any opioid-like effects, which minimizes the risk of misuse or diversion. It also has a safety profile that’s hard to beat—it brings someone out of a dangerous overdose without creating new problems. In rare cases, someone might react with agitation if they have long-term opioid dependence, but respiratory recovery always takes priority.
Cheaper imported versions occasionally appear, but uncertain quality and unclear instructions muddy the waters. Naloxone’s widespread use, regulatory scrutiny, and standard dosing shine by comparison. Every time I’ve seen someone revived from certain death, naloxone gave them that chance.
Students now encounter naloxone training as part of high school health classes in some districts. College campuses keep kits alongside first-aid supplies. Public transit authorities train conductors and drivers. This isn’t just about responding to overdoses—it’s about removing shame and replacing silence with honest discussion. Families shattered by overdose often wish they had known about naloxone sooner.
Information must stay accurate, so trainers and program leaders draw on trusted sources: the National Institute on Drug Abuse, the Centers for Disease Control and Prevention, and evidence gathered by experienced harm reductionists. People see through scare tactics or exaggerated promises. Real-world stories and facts create buy-in across all backgrounds.
If the last decade taught us anything, it’s that crises demand direct answers. Naloxone remains the clearest path to survival for victims of opioid overdose. The lives saved so far prove that practical, science-backed interventions should trump fear or misunderstanding. Widespread community access, affordable supplies, and broad education need to stick around. Naloxone opens the door to second chances—for families, for communities, for anyone touched by this crisis.
Drug trends will continue to evolve, and new risks may appear. But as a nation, as communities, as individuals, being prepared means keeping tools like naloxone close. Every life saved through its use is a testament to work, advocacy, and solidarity. For now, that’s the standard that matters.